Norwalk, CT – July 21, 2023 – LifeSpan Vision Ventures today announced an investment in Fauna Bio, a first-of-its-kind biotech company that studies the protective genotypes across extreme biology to develop new therapies to improve human health and lifespan. Fauna Bio utilizes its drug discovery platform, Convergence™, to directly link extreme biological traits in mammals to human disease in a way that is scalable and high throughput. The company is running 8 discovery programs in various stages of development, with their lead program in late lead optimization for pulmonary fibrosis and targeting clinical entry in early 2025.
Andrew Worden, Founding Partner of LifeSpan Vision Ventures, stated: “Our investment in Fauna Bio furthers our mission of supporting companies that develop therapeutics focusing on longevity and aging reversal. Fauna Bio’s strong team, modality-agnostic platform and early-stage partnerships gives the company excellent prospects to succeed with its vision. We are excited to see this investment become a success as the team develops its pipeline of novel genetic targets and molecules that have the potential to improve treatment paradigms for a range of high unmet need diseases.”
About Fauna Bio
Fauna Bio is a first-of-its-kind biotech company that studies the protective genotypes across extreme biology to develop new therapies to improve human health and lifespan. Fauna Bio utilizes its drug discovery platform, Convergence™, to directly link extreme biological traits in mammals to human disease in a way that is scalable and high throughput. The company is currently pursuing initial discovery programs in various stages of development across pulmonary fibrosis, neuronal metabolism, obesity, and cardiac damage.
About LifeSpan Vision Ventures
Lifespan Vision Ventures invests in companies that develop therapeutics focusing on longevity and aging reversal.